The table below shows Avidity Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Q1 2020
Operating cash flow
-$124.83M
-$70.38M
-$48.97M
-$29.57M
-$19.68M
-$7.14M
Capital expenditure
$3.75M
$915.00K
$1.82M
$758.00K
$525.00K
$10.00K
Investing cash flow
$157.19M
-$32.75M
-$195.68M
-$175.47M
-$525.00K
-$10.00K
Dividends paid
-
-
-
RNA operating cash flow (10-K history)
Avidity Biosciences, Inc. reported operating cash flow of -$650.44M for fiscal year 2025. That is down 116.2% from -$300.87M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$9.65M (FY 2018) to -$650.44M. Figures come from the company's audited annual reports as filed with the SEC.
